KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Acadia Pharmaceuticals (ACAD) Leases (2019 - 2025)

Acadia Pharmaceuticals has reported Leases over the past 7 years, most recently at $47.4 million for Q4 2025.

  • Quarterly results put Leases at $47.4 million for Q4 2025, up 1.68% from a year ago — trailing twelve months through Dec 2025 was $47.4 million (up 1.68% YoY), and the annual figure for FY2025 was $47.4 million, up 1.68%.
  • Leases for Q4 2025 was $47.4 million at Acadia Pharmaceuticals, down from $49.7 million in the prior quarter.
  • Over the last five years, Leases for ACAD hit a ceiling of $63.1 million in Q1 2021 and a floor of $44.3 million in Q3 2024.
  • Median Leases over the past 5 years was $53.3 million (2023), compared with a mean of $53.8 million.
  • Biggest five-year swings in Leases: soared 678.82% in 2021 and later decreased 12.82% in 2024.
  • Acadia Pharmaceuticals' Leases stood at $58.3 million in 2021, then fell by 4.63% to $55.6 million in 2022, then fell by 6.69% to $51.9 million in 2023, then decreased by 10.19% to $46.6 million in 2024, then grew by 1.68% to $47.4 million in 2025.
  • The last three reported values for Leases were $47.4 million (Q4 2025), $49.7 million (Q3 2025), and $51.0 million (Q2 2025) per Business Quant data.